34º Congresso Mineiro de Cardiologia
1º Dia - 7/10/25
2º Dia - 7/11/25
3º Dia - 7/12/25

Tratamento da obesidade e impacto da doença CV Voltar

Pedro Wesley Rosário

Simpósio Conjunto SMC e DEIC (Cardiomiopatias) - Marcelo Imbroinisi Bittencourt e Estevão Lanna Figueiredo

Artigo Autor(es) Referência
Association of obesity and cardiovascular disease and progress in pharmacotherapy: what is next for obesity? Mallah Manthar Ali, Soomro Tahmina, Noreen Sobia, Ali Mukhtiar, Kafle Akriti, Khatoon Nafeesa, Naveed Muhammad International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation. 2023 Mar; 46(Mar):14-25. doi: 10.1097/MRR.0000000000000565. pii: .
Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies. Binu Aditya John, Kapoor Nitin Heart international. 2024 ; 18():3-4. doi: 10.17925/HI.2024.18.1.1. pii: .
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Zile Michael R, Borlaug Barry A, Kramer Christopher M, Baum Seth J, Litwin Sheldon E, Menon Venu, Ou Yang, Weerakkody Govinda J, Hurt Karla C, Kanu Chisom, Murakami Masahiro, Packer Milton, Circulation. 2025 Mar; 151(Mar):656-668. doi: 10.1161/CIRCULATIONAHA.124.072679. pii: .
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? Ryan Donna H Reviews in endocrine & metabolic disorders. 2025 Oct; 26(Oct):805-813. doi: 10.1007/s11154-025-09967-4. pii: .
Nutrient-Stimulating Hormone-Based Therapies for Obesity. Cristancho Cagney, Kim Dong Wook, Apovian Caroline M Endocrinology and metabolism clinics of North America. 2025 Mar; 54(Mar):103-119. doi: 10.1016/j.ecl.2024.10.006. pii: S0889-8529(24)00086-0.
Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review. Islam Kazi N, Islam Rahib K, Tong Victoria T, Shami M Zaid, Allen Kaitlyn E, Brodtmann Jared R, Book Jordan A Cureus. 2024 Oct; 16(Oct):e71875. doi: 10.7759/cureus.71875. pii: e71875.
Obesity and cardiovascular disease: an ESC clinical consensus statement. Koskinas Konstantinos C, Van Craenenbroeck Emeline M, Antoniades Charalambos, Blüher Matthias, Gorter Thomas M, Hanssen Henner, Marx Nikolaus, McDonagh Theresa A, Mingrone Geltrude, Rosengren Annika, Prescott Eva B, European heart journal. 2024 Oct; 45(Oct):4063-4098. doi: 10.1093/eurheartj/ehae508. pii: .
Obesity and its treatment: Toward new approaches. Segrestin Bérénice, Cherifi Blandine Gatta Annales d'endocrinologie. 2025 Apr; 86(Apr):101712. doi: 10.1016/j.ando.2025.101712. pii: S0003-4266(25)00031-9.
Obesity update: cardiovascular risk and therapeutic innovations (focus on semaglutide and tirzepatide). Di Odoardo Luca Antonio Felice, Zucchetti Ottavio, Sciatti Edoardo, D'Isa Salvatore, D'Elia Emilia, Senni Michele European heart journal supplements : journal of the European Society of Cardiology. 2025 Mar; 27(Mar):iii137-iii142. doi: 10.1093/eurheartjsupp/suaf032. pii: .
Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction. Maki Kevin C, Kirkpatrick Carol F, Allison David B, Gadde Kishore M Expert review of endocrinology & metabolism. 2023 ; 18():307-319. doi: 10.1080/17446651.2023.2209176. pii: .
Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease. Ostrominski John W, Powell-Wiley Tiffany M Current atherosclerosis reports. 2024 Jan; 26(Jan):11-23. doi: 10.1007/s11883-023-01182-3. pii: .
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff A Michael, Brown-Frandsen Kirstine, Colhoun Helen M, Deanfield John, Emerson Scott S, Esbjerg Sille, Hardt-Lindberg Søren, Hovingh G Kees, Kahn Steven E, Kushner Robert F, Lingvay Ildiko, Oral Tugce K, Michelsen Marie M, Plutzky Jorge, Tornøe Christoffer W, Ryan Donna H, The New England journal of medicine. 2023 Dec; 389(Dec):2221-2232. doi: 10.1056/NEJMoa2307563. pii: .
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. Kosiborod Mikhail N, Abildstrøm Steen Z, Borlaug Barry A, Butler Javed, Rasmussen Søren, Davies Melanie, Hovingh G Kees, Kitzman Dalane W, Lindegaard Marie L, Møller Daniél V, Shah Sanjiv J, Treppendahl Marianne B, Verma Subodh, Abhayaratna Walter, Ahmed Fozia Z, Chopra Vijay, Ezekowitz Justin, Fu Michael, Ito Hiroshi, Lelonek Małgorzata, Melenovsky Vojtech, Merkely Bela, Núñez Julio, Perna Eduardo, Schou Morten, Senni Michele, Sharma Kavita, Van der Meer Peter, von Lewinski Dirk, Wolf Dennis, Petrie Mark C, The New England journal of medicine. 2023 Sep; 389(Sep):1069-1084. doi: 10.1056/NEJMoa2306963. pii: .
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. Kosiborod Mikhail N, Petrie Mark C, Borlaug Barry A, Butler Javed, Davies Melanie J, Hovingh G Kees, Kitzman Dalane W, Møller Daniél V, Treppendahl Marianne B, Verma Subodh, Jensen Thomas J, Liisberg Karoline, Lindegaard Marie L, Abhayaratna Walter, Ahmed Fozia Z, Ben-Gal Tuvia, Chopra Vijay, Ezekowitz Justin A, Fu Michael, Ito Hiroshi, Lelonek Małgorzata, Melenovský Vojtěch, Merkely Bela, Núñez Julio, Perna Eduardo, Schou Morten, Senni Michele, Sharma Kavita, van der Meer Peter, Von Lewinski Dirk, Wolf Dennis, Shah Sanjiv J, The New England journal of medicine. 2024 Apr; 390(Apr):1394-1407. doi: 10.1056/NEJMoa2313917. pii: .
Shifting Tides Offer New Hope For Obesity. Rosen Clifford J, Ingelfinger Julie R The New England journal of medicine. 2022 07; 387(07):271-273. doi: 10.1056/NEJMe2206939. pii: .
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, as potential (off-label) anti-obesity agents and effects on cardiovascular risk: A systematic review and meta-analysis. Choi Hye Duck, Kim Hyeon Kyeong International journal of clinical pharmacology and therapeutics. 2025 Mar; doi: 10.5414/CP204749. pii: .
Tirzepatide Once Weekly for the Treatment of Obesity. Jastreboff Ania M, Aronne Louis J, Ahmad Nadia N, Wharton Sean, Connery Lisa, Alves Breno, Kiyosue Arihiro, Zhang Shuyu, Liu Bing, Bunck Mathijs C, Stefanski Adam, The New England journal of medicine. 2022 07; 387(07):205-216. doi: 10.1056/NEJMoa2206038. pii: .
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. Aronne Louis J, Horn Deborah Bade, le Roux Carel W, Ho Wayne, Falcon Beverly L, Gomez Valderas Elisa, Das Sagar, Lee Clare J, Glass Leonard C, Senyucel Cagri, Dunn Julia P, The New England journal of medicine. 2025 Jul; 393(Jul):26-36. doi: 10.1056/NEJMoa2416394. pii: .
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. Packer Milton, Zile Michael R, Kramer Christopher M, Baum Seth J, Litwin Sheldon E, Menon Venu, Ge Junbo, Weerakkody Govinda J, Ou Yang, Bunck Mathijs C, Hurt Karla C, Murakami Masahiro, Borlaug Barry A, The New England journal of medicine. 2025 Jan; 392(Jan):427-437. doi: 10.1056/NEJMoa2410027. pii: .
Tirzepatide for Obesity Treatment and Diabetes Prevention. Jastreboff Ania M, le Roux Carel W, Stefanski Adam, Aronne Louis J, Halpern Bruno, Wharton Sean, Wilding John P H, Perreault Leigh, Zhang Shuyu, Battula Ramakrishna, Bunck Mathijs C, Ahmad Nadia N, Jouravskaya Irina, The New England journal of medicine. 2025 Mar; 392(Mar):958-971. doi: 10.1056/NEJMoa2410819. pii: .
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. Malhotra Atul, Grunstein Ronald R, Fietze Ingo, Weaver Terri E, Redline Susan, Azarbarzin Ali, Sands Scott A, Schwab Richard J, Dunn Julia P, Chakladar Sujatro, Bunck Mathijs C, Bednarik Josef, The New England journal of medicine. 2024 Jun; doi: 10.1056/NEJMoa2404881. pii: .
Nenhuma revista foi definida para este congresso.